Doç. Dr. ELİF ATAĞ AKYÜREK

Yayın Ağı

Makaleler 37

1. Total cholesterol/high-density lipoprotein cholesterol ratio is a candidate predictor of survival outcomes in patients with metastatic renal cell carcinoma

AKTEPE O. H., YETGİNOĞLU Ö., AKARCA M. S., ŞENCAN C., ÜNAL A., Atag E., et al.

Scientific Reports , cilt.15, sa.1, 2025 (SCI-Expanded)

2. Prognostic importance of CD47 expression on survival of colorectal cancer

Aktepe O. H., Kurtulan O., Dama P. E., Yildirim E. C., Terzi A., Kalyoncu S. A., et al.

BMC GASTROENTEROLOGY , cilt.25, sa.1, 2025 (SCI-Expanded, Scopus)

3. The Effect of HER2 Status on Gastric Cancer Survival and the Clinical Implications of the HER2-Low Definition: A Retrospective Study

Uzun M., Gokcek S., Kilinc M., EKİNCİ F., AVCI T., ERDOĞAN A. P., et al.

Medicina (Lithuania) , cilt.61, sa.9, 2025 (SCI-Expanded)

4. Survival-Related Prognostic Factors in Ovarian Cancer Patients Treated with Neoadjuvant Chemotherapy

Uzun M., CANASLAN K., Yildirim E. C., Gokcek S., Kaya E., Atag E., et al.

INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY , cilt.23, sa.3, 2025 (ESCI)

5. THSD7A as a novel prognostic factor for colorectal carcinoma

AKTEPE O. H., KURTULAN O., DAMA P. E., ARSLAN A. M., Atag E., ÜNER M., et al.

BMC GASTROENTEROLOGY , cilt.25, sa.1, 2025 (SCI-Expanded) Sürdürülebilir Kalkınma

6. Achieving treatment goals in older breast cancer patients receiving neoadjuvant chemotherapy

Yildirim E. C., Atag E., Semiz H. S., Unal O. U., Uzun M., Aksoy S. Ö., et al.

SCIENTIFIC REPORTS , cilt.15, sa.1, 2025 (SCI-Expanded, Scopus)

7. Prognostic factors and outcomes of adjuvant and first-line metastatic treatments in melanoma a Turkish oncology group study

Majidova N., Arak H., ÖZALP F. R., BAŞ O., Koker G. O., Ozmarasalı E. B., et al.

Scientific reports , cilt.15, sa.1, ss.3200, 2025 (SCI-Expanded)

8. Effect of HER2/CEP17 ratio on survival in metastatic HER2-positive gastric cancer, multicenter study

Sekmek S., Karahan I., Ucar G., Ceylan F., Bayram D., Seven I., et al.

Clinical and Translational Oncology , cilt.26, sa.8, ss.1878-1885, 2024 (SCI-Expanded, Scopus)

9. Does immunohistochemical marker conversion affect the prognosis in breast cancer patients receiving neoadjuvant chemotherapy?

Uzun M., Atag E., Caliskan Yildirim E., Keser M., Semiz H. S., Unal O. U.

Scientific reports , cilt.14, sa.1, ss.14651, 2024 (SCI-Expanded, Scopus)

10. Pan-immune-inflammation value as a prognostic tool for overall survival and disease-free survival in non-metastatic muscle-invasive bladder cancer.

Kayar R., Bastug Y., Tokuc E., Topaktas R., Akyurek E., Kayar K., et al.

International urology and nephrology , cilt.56, ss.509-518, 2024 (SCI-Expanded) Sürdürülebilir Kalkınma

11. The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and endocrine therapy: A multicentric retrospective study.

ÇALIŞKAN YILDIRIM E., ATAĞ E., Coban E., Umit Unal O., Celebi A., Keser M., et al.

Breast (Edinburgh, Scotland) , cilt.70, ss.56-62, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

12. Tailoring adjuvant chemotherapy by circulating tumor DNA (ctDNA) in older patients with stage II-III colon cancer

Akagunduz B., Guven D. C., Ozer M., Okten I. N., Atag E., Unek İ. T., et al.

JOURNAL OF GERIATRIC ONCOLOGY , cilt.14, sa.2, 2023 (SCI-Expanded) Sürdürülebilir Kalkınma

13. The Relationship Between Chemotherapy Related Neutropenia and Survival in Ovarian Cancer

ATAĞ AKYÜREK E., CAN B., AKAGÜNDÜZ B., SANCI M., SEMİZ H. S.

Eurasian Journal of Medical Investigation , cilt.7, sa.1, ss.58-62, 2023 (Hakemli Dergi) Sürdürülebilir Kalkınma

14. Supportive Care or Specific Treatment? On Elderly Cancer Patients

GÖKÇAY S., ATAĞ AKYÜREK E., TANRIKULU ŞİMŞEK E.

Eurasian Journal of Medical Investigation , cilt.7, sa.2, ss.123-129, 2023 (Hakemli Dergi) Sürdürülebilir Kalkınma

15. cERBB-2/Her-2 Neu Overexpression and Prognostic Significance in Uterine Carcinosarcoma.

SEMİZ H. S., PALA E. E., CAN B., ATAĞ E., GÜNGÖR H., SANCI M.

Turk patoloji dergisi , cilt.39, ss.55-63, 2023 (ESCI, Scopus, TRDizin)

16. Syrian Refugee and Turkish Women with Breast Cancer: A Comparison on Clinicopathological Features and Survival.

Atag E., Gokcay S., Tanrikulu Simsek E., Aslan F., Yetisir A. E., Sari M.

Archives of Iranian medicine , cilt.26, sa.1, ss.29-35, 2023 (SCI-Expanded)

17. Does neoadjuvant chemotherapy provide any benefit for surgical de-escalation in luminal B, HER2(-) breast cancers?

Aktas A., Gunay-Gurleyik M., Aker F., Kaan-Akgok Y., Atag E.

Cirugia y cirujanos , cilt.91, sa.2, ss.186-194, 2023 (SCI-Expanded)

18. CD47 (don't eat me signal) expression levels and its relationship with clinicopathologic features in early-stage prostate carcinoma

Semiz H. S., Kucuk U., Kisa E., Keskinkılıç M., Suyun D. E., Arayici M. E., et al.

PROSTATE , cilt.82, sa.16, ss.1564-1571, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

19. Factors Influencing Mortality of Metastatic Bladder Cancer: A Single-Center Experience

Atağ E., Sarı M., Çoban E., Şimşek E. T.

Eurasian Journal of Medical Investigation , cilt.6, sa.4, ss.470-476, 2022 (Hakemli Dergi) Sürdürülebilir Kalkınma

20. Treatment Approach for Muscle-Invasive Bladder Cancer: Real-Life Data From a Single Center

ATAĞ E., ÇOBAN E., SARI M., TANRIKULU ŞİMŞEK E., TOPAKTAŞ R., GÜMRÜKÇÜ G., et al.

Eurasian Journal of Medical Investigation , cilt.7, sa.1, ss.22-31, 2022 (Hakemli Dergi) Sürdürülebilir Kalkınma

21. What Is Your Choice for Androgen Deprivation Therapy in Metastatic Prostate Carcinoma: Surgical or Medical?

Semiz H. S., Kisa E., Caliskan Yildirim E., Atag E., Arayici M. E., Muezzinoglu T., et al.

Turkish journal of urology , cilt.48, sa.4, ss.287-293, 2022 (ESCI, Scopus, TRDizin)

22. Evaluation of Effect and Side Effects of Pemetrexed in Patients with Advanced-Stage Lung Adenocarcinoma

Gökçay S., Atağ E.

ACTA ONCOLOGICA TURCICA , cilt.55, sa.1, ss.25-33, 2022 (Hakemli Dergi)

23. In Which Luminal Breast Cancers Might NeoadjuvantChemotherapy Be Appropriate to Achieve a PathologicalComplete Response in Axillary Lymph Nodes?

Şimşek E. T., Çoban E., Atağ E., Sarı M., Gürleyik M. G.

Eurasian Journal of Medical Investigation , cilt.6, sa.2, ss.184-189, 2022 (Hakemli Dergi) Sürdürülebilir Kalkınma

24. The Effect of FDG-PET/CT on Clinical Prognostic Staging of Breast Cancer Patients being Planned Neoadjuvant Treatment.

Simsek E. T., Coban E., Atag E., Gungor S., Aker F., Sari M.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP , cilt.32, sa.2, ss.181-185, 2022 (SCI-Expanded)

25. Deficient Mismatch Repair and Lymphocytic Response to Tumor as Prognostic Markers in Stage II Colon Cancer Patients.

Sari M., Atag E., Demir T., Simsek E. T., Coban E., Cikrikcioglu M.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP , cilt.32, sa.2, ss.186-192, 2022 (SCI-Expanded)

26. Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences.

Tural D., Ölmez Ö. F., Sümbül A. T., Artaç M., Özhan N., Akar E., et al.

European urology focus , cilt.7, sa.5, ss.1061-1066, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma

27. Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab

Tural D., Olmez O. F., Sumbul A. T., Ozhan N., ÇAKAR B., Kostek O., et al.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY , cilt.26, sa.8, ss.1506-1513, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma

28. The Role of FDG PET/CT to Evaluation of Axillary Lymph Nodes after Neoadjuvant Chemotherapy in Breast Cancer.

Simsek E. T., Coban E., Atag E., Gungor S., Sari M., Gurleyik G.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP , cilt.30, sa.7, ss.792-797, 2021 (SCI-Expanded)

29. Factors influencing physical activity in patients with colorectal cancer

Kucukvardar D., KARADİBAK D., Ozsoy I., Atag Akyurek E., YAVUZŞEN T.

IRISH JOURNAL OF MEDICAL SCIENCE , cilt.190, sa.2, ss.539-546, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

30. Breast Cancer

ATAĞ AKYÜREK E.

ENCYCLOPEDIA OF BIOMEDICAL GERONTOLOGY, VOL 1 , ss.306-314, 2020 (SCI-Expanded) Sürdürülebilir Kalkınma

31. Prevalence of depressive symptoms in elderly cancer patients receiving chemotherapy and influencing factors

Atag E., Mutlay F., Soysal P., Semiz H. S., KAZAZ S. N., Keser M., et al.

PSYCHOGERIATRICS , cilt.18, sa.5, ss.365-370, 2018 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

32. Risk Adaptive Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer

Atag E., KARAOĞLU A., Kucuk O.

UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY , cilt.16, sa.2, ss.57-62, 2017 (ESCI) Sürdürülebilir Kalkınma

33. Response to Cabazitaxel Beyond 20 Cycles in A Patient with Penile Metastasis of Prostate Cancer: A Case Report

Atag E., Semiz H. S., KAZAZ S. N., Tuna E. B., Ozdogan Ö., Bozkurt O., et al.

UROLOGY JOURNAL , cilt.14, sa.1, ss.2985-2988, 2017 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

34. The Rate of Neoadjuvant Chemotherapy Use in Muscle Invasive Bladder Cancer and The Approach of Urologists in Turkey

ÜÇER O., Albaz A. C., Atag E., KARAOĞLU A., MÜEZZİNOĞLU T.

UROLOGY JOURNAL , cilt.13, sa.5, ss.2841-2844, 2016 (SCI-Expanded) Sürdürülebilir Kalkınma

35. Epstein Barr Virus Associated Lymphoepithelioma Like Carcinoma of the Esophagogastric Junction and Stomach A Case Report and Review of the Literature

ATAĞ E., KAZAZ S. N., SEMİZ H. S., ÜNEK İ. T., SARIOĞLU S., YAVUZŞEN T.

Journal of Clinical Experimental Oncology , cilt.5, sa.06, 2016 (Hakemli Dergi)

36. Prognostic Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio for Patients with Neuroendocrine Tumors: An Izmir Oncology Group Study

Salman T., KAZAZ S. N., Varol U., Oflazoglu U., ÜNEK İ. T., KÜÇÜKZEYBEK Y., et al.

CHEMOTHERAPY , cilt.61, sa.6, ss.281-286, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

37. Predictors of Mortality in Critically Ill Patients with Poisoning: A Single Center Experience

COŞKUN R., GÜNDOĞAN K., ATAĞ E., AKBUDAK İ. H., ÖZTÜRK A., GÜVEN M., et al.

Türkiye Klinikleri Tıp Bilimleri Dergisi , cilt.33, sa.5, ss.1274-1282, 2013 (Scopus)

Kitaplar 5

Metrikler

Yayın

139

Yayın (WoS)

Yayın (Scopus)

Atıf (WoS)

153

H-İndeks (WoS)

Atıf (Scopus)

146

H-İndeks (Scopus)

Atıf (Scholar)

194

H-İndeks (Scholar)

Atıf (Sobiad)

H-İndeks (Sobiad)

Atıf (Diğer Toplam)

Açık Erişim

BM Sürdürülebilir Kalkınma Amaçları

Yayınlar & Eserler